Tilray, Inc. Stock price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 805M 1.09B | Sales 2025 * | 885M 1.2B | Capitalization | 1.86B 2.52B |
---|---|---|---|---|---|
Net income 2024 * | -155M -210M | Net income 2025 * | -72M -97.66M | EV / Sales 2024 * | 2.57 x |
Net Debt 2024 * | 209M 283M | Net Debt 2025 * | 174M 236M | EV / Sales 2025 * | 2.3 x |
P/E ratio 2024 * |
-10.9
x | P/E ratio 2025 * |
-20.8
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.65% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 21-04-29 |
Carl Merton
DFI | Director of Finance/CFO | - | 21-04-29 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 21-04-29 |
David Clanachan
BRD | Director/Board Member | 62 | 21-04-29 |
Walter Robb
BRD | Director/Board Member | 70 | 21-04-29 |
1st Jan change | Capi. | |
---|---|---|
+33.85% | 701B | |
+26.24% | 571B | |
+1.17% | 381B | |
+20.85% | 334B | |
+16.35% | 319B | |
+1.13% | 210B | |
+2.59% | 210B | |
-6.67% | 201B | |
-3.18% | 157B |